The in silico EGFR-mutant lung adenocarcinoma (ISELA) model presented in this paper is a predictive and reliable mechanistic model of tumor growth evolution for patients treated with gefitinib with TTP as primary outcome. This evidence concerns the gene EGFR and lung adenocarcinoma.